Company profile
Aytu BioPharma, Inc.
NASDAQ: AYTU · Healthcare · Drug Manufacturers - Specialty & Generic
#400 of 1,418 Healthcare companies by revenue29th-percentile growth
EA Score
53DFH 55DQ 57GM 35SS 61
v0.1 · 65/100 weight · provisional
↑ disclosure history, return on assets · ↓ 3-yr revenue growth, revenue growth (YoY)
Methodology →Revenue TTM
$56.6M
Rev growth YoY (TTM)
-18.2%
Net income (FY)
-$13.6M
Employees
83
as of 2026-08-21
Market cap
$24.5M
as of 2026-08-21
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$66.4M$66.4M2025
Net income-$13.6M-$13.6M2025
Operating income-$7.8M-$7.8M2025
Total assets$124.2M$124.2M2025
Liabilities$97.1M$97.1M2023
Equity$19.0M$19.0M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY20
FY21
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2024
By product
Consumer Health100%
By geography
UNITED STATES100%
Non-US0%
The read
What is Aytu BioPharma, Inc.’s revenue?
Aytu BioPharma, Inc. booked $66.4M in FY2025 revenue, contracting 18% year over year — slower than 71% of Healthcare companies we track, at a -20.4% net margin.
Peers · Healthcare
Praxsyn Corporation——Pro-Dex, Inc.86AExagen Inc.55CEnanta Pharmaceuticals, Inc.55CCosmos Health Inc.55CConcord Medical Services Holdings Limited59CNeighbors
Arapahoe →Key facts
CEOJoshua R. Disbrow
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersEnglewood, CO
ExchangeNASDAQ: AYTU
Employees83
IPO date2008-09-25
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.